Assignee
SIGNPATH PHARMA INC
US·19 granted patents·16 pending applications·133 citations·filing 2013–2023
Top patents by PatentIndex Score
35 records- 0197US10117881B2Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathiesSIGNPATH PHARMA INC·Filed 2016·Granted Nov 6, 2018·16 cites·18 claims
- 0296US10449193B2Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathiesSIGNPATH PHARMA INC·Filed 2016·Granted Oct 22, 2019·13 cites·18 claims
- 0396US10238602B2Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathiesSIGNPATH PHARMA INC·Filed 2017·Granted Mar 26, 2019·16 cites·7 claims
- 0495US10357458B2Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier currentSIGNPATH PHARMA INC·Filed 2017·Granted Jul 23, 2019·16 cites·12 claims
- 0595US10349884B2Liposomal mitigation of drug-induced inhibition of the cardiac ikr channelSIGNPATH PHARMA INC·Filed 2017·Granted Jul 16, 2019·16 cites·20 claims
- 0694US9682041B2Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier currentSIGNPATH PHARMA INC·Filed 2014·Granted Jun 20, 2017·21 cites·14 claims
- 0793US10617639B2Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier currentSIGNPATH PHARMA INC·Filed 2016·Granted Apr 14, 2020·5 cites·16 claims
- 0892US10258691B2Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathiesSIGNPATH PHARMA INC·Filed 2015·Granted Apr 16, 2019·16 cites·10 claims
- 0985US10485768B2Treatment for glioblastomaSIGNPATH PHARMA INC·Filed 2016·Granted Nov 26, 2019·4 cites·7 claims
- 1083US10532045B2Liposomal mitigation of drug-induced inhibition of the cardiac IKr channelSIGNPATH PHARMA INC·Filed 2014·Granted Jan 14, 2020·6 cites·13 claims
- 1180US10975111B2Cardiopathy-reducing phosphodiester lipidsSIGNPATH PHARMA INC·Filed 2019·Granted Apr 13, 2021·3 cites·16 claims
- 1275US11746119B2Cardiopathy-reducing phosphodiester lipidsSIGNPATH PHARMA INC·Filed 2021·Granted Sep 5, 2023·0 cites·12 claims
- 1371US9170257B2Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcuminSIGNPATH PHARMA INC·Filed 2013·Granted Oct 27, 2015·1 cites·17 claims
- 1469US12551436B2Dosing regimens for treatment of proliferative disordersSIGNPATH PHARMA INC·Filed 2023·Granted Feb 17, 2026·0 cites·10 claims
- 1566US11643424B2Cardiopathy-reducing phosphodiester lipidsSIGNPATH PHARMA INC·Filed 2021·Granted May 9, 2023·0 cites·14 claims
- 1665US2019321293A1Liposomal Mitigation of Drug-Induced Long QT Syndrome and Potassium Delayed-Rectifier CurrentSIGNPATH PHARMA INC·Filed 2019·Application pending·0 cites
- 1765US2024270765A2Cardioprotective lipids and methods of useSIGNPATH PHARMA INC·Filed 2023·Application pending·0 cites
- 1865US2019388422A1Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathiesSIGNPATH PHARMA INC·Filed 2019·Application pending·0 cites
- 1964US2020108056A1Liposomal Mitigation of Drug-Induced Inhibition of the Cardiac IKR ChannelSIGNPATH PHARMA INC·Filed 2019·Application pending·0 cites
- 2063US2019167585A1Protective Effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC Against Drugs that Cause ChannelopathiesSIGNPATH PHARMA INC·Filed 2019·Application pending·0 cites
- 2159US2020046652A1Treatment for glioblastomaSIGNPATH PHARMA INC·Filed 2019·Application pending·0 cites
- 2258US11813356B2Dosing regimens for treatment of proliferative disordersSIGNPATH PHARMA INC·Filed 2019·Granted Nov 14, 2023·0 cites·10 claims
- 2358US2023042703A1Cardioprotective Lipid and Method of UseSIGNPATH PHARMA INC·Filed 2022·Application pending·0 cites
- 2453US2014234402A1Intravenous Infusion of Curcumin and a Calcium Channel BlockerSIGNPATH PHARMA INC·Filed 2014·Application pending·0 cites
- 2551US2024180852A1Treatment for malignant pleural effusion in humansSIGNPATH PHARMA INC·Filed 2022·Application pending·0 cites
- 2649US2024091242A1Lipids that reduce lung damage, improve pulmonary function and decrease pro-inflammatory cytokinesSIGNPATH PHARMA INC·Filed 2022·Application pending·0 cites
- 2748US12004868B2Liposomal mitigation of drug-induced inhibition of the cardiac IKr channelSIGNPATH PHARMA INC·Filed 2019·Granted Jun 11, 2024·0 cites·10 claims
- 2848US11806401B2Prevention of drug-induced atrio-ventricular blockSIGNPATH PHARMA INC·Filed 2017·Granted Nov 7, 2023·0 cites·5 claims
- 2948US2019008878A1Compositions and method for reducing cardiotoxicitySIGNPATH PHARMA INC·Filed 2018·Application pending·0 cites
- 3046US2015147385A1Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disordersSIGNPATH PHARMA INC·Filed 2014·Application pending·0 cites
- 3144US10739353B2Suppression of cytokine release and cytokine stormSIGNPATH PHARMA INC·Filed 2015·Granted Aug 11, 2020·0 cites·19 claims
- 3244US2020360300A1Suppression of Cytokine Release and Cytokine StormSIGNPATH PHARMA INC·Filed 2020·Application pending·0 cites
- 3343US2015377894A1Method and System for Measuring the Pharmacokinetics of Liposomal Curcumin and its Metabolite TetrahydrocurcuminSIGNPATH PHARMA INC·Filed 2015·Application pending·0 cites
- 3439US2017252311A1Sphingosine kinase inhibitors and ceramide for maintenance therapy of glioblastomaSIGNPATH PHARMA INC·Filed 2017·Application pending·0 cites
- 3538US2016287532A1Curcumin for treating intervertebral disc diseaseSIGNPATH PHARMA INC·Filed 2016·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →